MASH Clinical

We are in Paris! For the next two days, we will be in Paris for our Executive Board Meeting, where we will discuss the current state of affairs and keep each other updated on our respective activities. A special thanks to Echosens for hosting this important meeting. #GRIPonMASH #mash #consortium #meeting

We’re excited to announce, that Alina Saidi’s, a PhD student in the Department of Internal Medicine at Sint Franciscus Gasthuis, abstract titled "𝗟𝗶𝘃𝗲𝗿 𝗙𝗶𝗯𝗿𝗼𝘀𝗶𝘀 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝘀 𝗢𝗯𝗲𝘀𝗲 𝗦𝘂𝗯𝗷𝗲𝗰𝘁𝘀 𝗮𝘁 𝗛𝗶𝗴𝗵𝗲𝘀𝘁 𝗥𝗶𝘀𝗸 𝗳𝗼𝗿 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲" has been selected for an oral presentation at the upcoming 𝗔𝗻𝗻𝘂𝗮𝗹 𝗗𝘂𝘁𝗰𝗵 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 (𝗔𝗗𝗗𝗥𝗠) 𝟮𝟬𝟮𝟰. The abstract investigates the relationship between liver fibrosis, as measured by the Fibrosis-4 (FIB-4) index, and cardiovascular risk in patients with severe obesity. It reveals that individuals with a high FIB-4 score face increased cardiovascular risk, highlighting the importance of assessing liver fibrosis to identify those who are at the highest cardiovascular risk. Alina Saidi is honoured to share these findings at the ADDRM, which will take place from November 14 and 15 in Wageningen. More details about the meeting can be found here: https://www.addrm.online/

We’re excited to announce, that Weiwei X., a master's student of epidemiology at Universiteit Utrecht, abstract titled "𝗛𝗲𝗽𝗮𝘁𝗶𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗲𝘀 𝗰𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗿𝗶𝘀𝗸 𝗶𝗻 𝗧𝟮𝗗𝗠 𝗶𝗻𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁 𝗳𝗿𝗼𝗺 𝗼𝘁𝗵𝗲𝗿 𝗰𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗿𝗶𝘀𝗸 𝗳𝗮𝗰𝘁𝗼𝗿𝘀: 𝗥𝗲𝗽𝗼𝗿𝘁 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗔𝗹𝗲𝗖𝗮𝗿𝗱𝗶𝗼 𝗧𝗿𝗶𝗮𝗹" has been selected for an oral presentation at the upcoming 𝗔𝗻𝗻𝘂𝗮𝗹 𝗗𝘂𝘁𝗰𝗵 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 (𝗔𝗗𝗗𝗥𝗠) 𝟮𝟬𝟮𝟰. The abstract, which stems from the AleCardio study from Julius Clinical, represents a significant contribution to the field of diabetes research. Weiwei XU is honored to share these findings at the ADDRM, which will take place from November 14th-15th in Wageningen. More details about the meeting can be found here: https://www.addrm.online/

In our recent MASH webinar, we were honored to have Prof. Maja Thiele present on '𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗰𝗼𝗻𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗠𝗔𝗦𝗟𝗗 𝗻𝗼𝗺𝗲𝗻𝗰𝗹𝗮𝘁𝘂𝗿𝗲'. Hosted by Prof. Manuel Castro Cabezas and Prof. Christophe Moreno, this session offered profound insights into the impact of disease prevalence on non-invasive diagnostic methods, the role of lifestyle changes in patient care, and the enhancement of MASH management through clinical pathways. 𝗧𝗵𝗲 𝗿𝗲𝗽𝗹𝗮𝘆 𝗶𝘀 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲. 𝗪𝗮𝘁𝗰𝗵 𝗵𝗲𝗿𝗲: https://lnkd.in/dBK7ZQha

Join us this afternoon for the 11th MASH Webinar! Calendar already full? When you register, you will automatically receive an email allowing you to replay the webinar at your own convenience. We look forward to having you there! #webinar #MASH #MASLD #liverdisease #research

It's the final week of Fatty Liver Month. Therefore we would like to share essential information about MASLD and MASH and the urgent need for early detection of these diseases. MASLD is estimated to affect 30% of the adult global population, with a higher prevalence in high-risk groups such as patients with type 2 diabetes, metabolic syndrome, hypertension, and obesity. MASLD has become the most common liver disease in many countries. 🌍 MASH, a progressive stage of MASLD, causes even more liver damage. Fortunately, MASH can be reversed through targetted lifestyle interventions. Early detection can thus prevent a lot of unnecessary harm. Join us in making a difference! Follow us for the latest updates, valuable resources, and inspiring stories. Together, we can combat MASH and MASLD and enhance liver health globally. #FattyLiverMonth #LiverHealth #MASH #MASLD #earlydetection

𝗖𝗼𝘂𝗻𝘁𝗱𝗼𝘄𝗻 𝗕𝗲𝗴𝗶𝗻𝘀: 𝗢𝘂𝗿 𝟭𝟭𝘁𝗵 𝗠𝗔𝗦𝗛 𝗪𝗲𝗯𝗶𝗻𝗮𝗿! - 𝗝𝘂𝘀𝘁 𝟭 𝗪𝗲𝗲𝗸 𝗔𝘄𝗮𝘆! Join us and our guest speaker, Prof. Maja Thiele, as we delve into: - Is the MASLD nomenclature of prognostic relevance? - Do we need to re-validate all NILTs after the new nomenclature? - Considerations for "the new kid in town": MetALD 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/dBK7ZQha #webinar #MASH #MASLD #liverdisease #research

Today, June 13 is Global Fatty Liver Day! This day is also the start of Fatty Liver Month. This month, we’re excited to share essential information, uplifting stories, and practical tips to keep your liver healthy. Let’s honor the resilience of our livers and take proactive steps towards a healthier future together. ❤️ Take Action: ✔ Share this post to inform your friends and family. ✔ Schedule a check-up with your healthcare provider. ✔ Adopt a healthier lifestyle to reduce your risk. Join us in making a difference! Follow us for the latest updates, valuable resources, and inspiring stories. Together, we can combat MASH and MASLD and enhance liver health globally. #FattyLiverDay #FattyLiverMonth #LiverHealth #MASH #MASLD

During the 2024 𝐄𝐀𝐒 𝐚𝐧𝐝 𝐄𝐀𝐒𝐋 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬𝐞𝐬, our talented researchers have made notable contributions by presenting their posters Alina Saidi presented "𝐋𝐢𝐯𝐞𝐫 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐞𝐬 𝐎𝐛𝐞𝐬𝐞 𝐒𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐚𝐭 𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐑𝐢𝐬𝐤 𝐟𝐨𝐫 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: 𝐓𝐡𝐞 𝐀𝐬𝐬𝐢𝐬𝐢 𝐒𝐭𝐮𝐝𝐲." Her research emphasizes liver fibrosis as a crucial marker for cardiovascular risk in obese individuals, providing valuable insights for early intervention and management. Willy Theel MSc presented: "𝐄𝐟𝐟𝐞𝐜𝐭 𝐨𝐟 𝐏𝐫𝐚𝐯𝐚𝐬𝐭𝐚𝐭𝐢𝐧 𝐨𝐧 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐢𝐧 𝐚𝐧 𝐄𝐥𝐝𝐞𝐫𝐥𝐲 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐚𝐧𝐝 𝐋𝐢𝐯𝐞𝐫 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬." His work was not only highly recognized but also selected as a top-rated poster presentation, underscoring its importance. His findings explore the potential benefits of pravastatin in reducing cardiovascular risks among elderly patients with obesity and liver fibrosis. For a detailed look at the presented posters, visit the MASH Clinical website: https://lnkd.in/d_QAH32A

𝗪𝗲 𝗮𝗿𝗲 𝗼𝗻𝗹𝘆 𝟯 𝘄𝗲𝗲𝗸𝘀 𝗮𝘄𝗮𝘆 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗠𝗔𝗦𝗛 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 '𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗡𝗲𝘄 𝗠𝗔𝗦𝗟𝗗 𝗡𝗼𝗺𝗲𝗻𝗰𝗹𝗮𝘁𝘂𝗿𝗲' 𝘄𝗶𝘁𝗵 𝗣𝗿𝗼𝗳. Maja Thiele During this webinar, our speaker and hosts will dive into the following topics: - Is the MASLD nomenclature of prognostic relevance? - Do we need to re-validate all NILTs after the new nomenclature? - Considerations for "the new kid in town": MetALD 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/dBK7ZQha #webinar #MASH #MASLD #liverdisease #research